Molecular landscape of anti-drug antibodies reveals the mechanism of the immune response following treatment with TNFα antagonists
Open accessPublished version of a preprint
Abstract
Drugs formulated from monoclonal antibodies (mAbs) are clinically effective in various diseases. Repeated administration of mAbs, however, elicits an immune response in the form of anti-drug-antibodies (ADA), thereby reducing the drug's efficacy. Notwithstanding their importance, the molecular landscape of ADA and the mechanisms involved in their formation are not fully understood. Using a newly developed quantitative bio-immunoassay, we found that ADA concentrations specific to TNFα antagonists can exceed extreme concentrations of 1 mg/ml with a wide range of neutralization capacity. Our data further suggest a preferential use of the λ light chain in a subset of neutralizing ADA. Moreover, we show that administration of TNFα antagonists result in a vaccine-like response whereby ADA formation is governed by the extrafollicular T cell-independent immune response. Our bio-immunoassay coupled with insights on the nature of the immune response can be leveraged to improve mAb immunogenicity assessment and facilitate improvement in therapeutic intervention strategies.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Immunogenicity negatively affects therapeutic efficacy and impacts safety through the induction of adverse drug reactions.
“Immunogenicity negatively affects therapeutic efficacy and impacts safety through the induction of adverse drug reactions [30].”
From Computational and artificial intelligence-based methods for antibody development (2023) · cites this paper as [30]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Cox, J., & Mann, M. (2008) · Nature Biotechnology · doi:10.1038/nbt.1511 · Cited by 14,855 · see citing works
Andromeda: A Peptide Search Engine Integrated into the MaxQuant Environment
Cox, J., Neuhauser, N., Michalski, A., Scheltema, R. A., Olsen, J. V., & Mann, M. (2011) · Journal of Proteome Research · doi:10.1021/pr101065j · Cited by 5,349 · see citing works
Cox, J., Hein, M. Y., Luber, C. A., Paron, I., Nagaraj, N., & Mann, M. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m113.031591 · Cited by 5,180 · see citing works
Infliximab Maintenance Therapy for Fistulizing Crohn's Disease
Sands, B. E., Anderson, F., Bernstein, C. N., Chey, W. Y., Feagan, B. G., Fedorak, R. N., Kamm, M. A., Korzenik, J. R., Lashner, B. A., Onken, J. E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030815 · Cited by 2,222 · see citing works
Pasparakis, M., Alexopoulou, L., Episkopou, V., & Kollias, G. A. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.184.4.1397 · Cited by 1,160 · see citing works
The safety and side effects of monoclonal antibodies
Hansel, T. T., Kropshofer, H., Singer, T., Mitchell, J. A., & George, A. J. T. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3003 · Cited by 1,151 · see citing works
Development trends for human monoclonal antibody therapeutics
Nelson, A. L., Dhimolea, E., & Reichert, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3229 · Cited by 1,027 · see citing works
Origin of Murine B Cell Lineages
Kantor, A. B., & Herzenberg, L. A. (1993) · Annual Review of Immunology · doi:10.1146/annurev.iy.11.040193.002441 · Cited by 578 · see citing works
Immunogenicity of protein therapeutics
Groot, A. S. D., & Scott, D. W. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.07.011 · Cited by 545 · see citing works
IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G
von Pawel‐Rammingen, U., Johansson, B. P., & Björck, L. (2002) · The EMBO Journal · doi:10.1093/emboj/21.7.1607 · Cited by 475 · see citing works
The Increasingly Human and Profitable Monoclonal Antibody Market
Grilo, A. L., & Mantalaris, A. (2018) · Trends in biotechnology · doi:10.1016/j.tibtech.2018.05.014 · Cited by 468 · see citing works
Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis
van Schouwenburg, P. A., Rispens, T., & Wolbink, G. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.4 · Cited by 441 · see citing works
Immunogenicity to Biotherapeutics – The Role of Anti-drug Immune Complexes
Krishna, M., & Nadler, S. G. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00021 · Cited by 389 · see citing works
Immunogenicity of protein therapeutics: The key causes, consequences and challenges
Baker, M., Reynolds, H. M., Lumicisi, B., & Bryson, C. J. (2010) · Self/Nonself · doi:10.4161/self.1.4.13904 · Cited by 372 · see citing works
Vincent, F. B., Morand, E. F., Murphy, K., Mackay, F., Xavier Mariette, A., & Marcelli, C. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202545 · Cited by 356 · see citing works
Ungar, B., Chowers, Y., Yavzori, M., Picard, O., Fudim, E., Har‐Noy, O., Kopylov, U., Eliakim, R., & Ben‐Horin, S. (2013) · Gut · doi:10.1136/gutjnl-2013-305259 · Cited by 309 · see citing works
Self-citationHayakawa, K., Hardy, R. R., & Herzenberg, L. A. (1986) · European Journal of Immunology · doi:10.1002/eji.1830160423 · Cited by 301 · see citing works
Lee, J., Boutz, D. R., Chromikova, V., Joyce, M. G., Vollmers, C., Leung, K., Horton, A. P., DeKosky, B. J., Lee, C., Lavinder, J. J., et al. (2016) · Nature Medicine · doi:10.1038/nm.4224 · Cited by 278 · see citing works
Mitoma, H., Horiuchi, T., Hatta, N., Tsukamoto, H., Harashima, S., Kikuchi, Y., Otsuka, J., Okamura, S., Fujita, S., & Harada, M. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.11.060 · Cited by 271 · see citing works
Lavinder, J. J., Wine, Y., Giesecke‐Thiel, C., Ippolito, G. C., Horton, A. P., Lungu, O. I., Hoi, K. H., DeKosky, B. J., Murrin, E. M., Wirth, M. M., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1317793111 · Cited by 239 · see citing works
Self-citationBen‐Horin, S., Yavzori, M., Katz, L. H., Kopylov, U., Picard, O., Fudim, E., Coscas, D., Bar-Meir, S., Goldstein, I., & Chowers, Y. (2010) · Gut · doi:10.1136/gut.2009.201533 · Cited by 203 · see citing works
Self-citationTailoring anti-TNF therapy in IBD: drug levels and disease activity
Ben‐Horin, S., & Chowers, Y. (2014) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.253 · Cited by 192 · see citing works
Self-citationSvenson, M., Geborek, P., Saxne, T., & Bendtzen, K. (2007) · Rheumatology · doi:10.1093/rheumatology/kem261 · Cited by 189 · see citing works
DeKosky, B. J., Lungu, O. I., Park, D., Johnson, E. L., Charab, W., Chrysostomou, C., Kuroda, D., Ellington, A. D., Ippolito, G. C., Gray, J. J., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525510113 · Cited by 189 · see citing works
Wenig, K., Chatwell, L., von Pawel‐Rammingen, U., Björck, L., Huber, R., & Sondermann, P. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407965101 · Cited by 170 · see citing works
Robinson, J. E., Hastie, K. M., Cross, R. W., Yenni, R. E., Elliott, D. H., Rouelle, J. A., Kannadka, C. B., Smira, A. R., Garry, C. E., Bradley, B. T., et al. (2016) · Nature Communications · doi:10.1038/ncomms11544 · Cited by 168 · see citing works
Ademokun, A., Wu, Y., Martin, V., Mitra, R., Sack, U., Baxendale, H., Kipling, D., & Dunn‐Walters, D. K. (2011) · Aging Cell · doi:10.1111/j.1474-9726.2011.00732.x · Cited by 139 · see citing works
Molecular deconvolution of the monoclonal antibodies that comprise the polyclonal serum response
Wine, Y., Boutz, D. R., Lavinder, J. J., Miklos, A. E., Hughes, R. A., Hoi, K. H., Jung, S. T., Horton, A. P., Murrin, E. M., Ellington, A. D., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213737110 · Cited by 135 · see citing works
Self-citationRohner, G. B., Pulickal, A. S., der Zijde, C. M. J., Snape, M. D., & Pollard, A. J. (2009) · Blood · doi:10.1182/blood-2009-03-211052 · Cited by 119 · see citing works
Putnam, W. S., Prabhu, S., Zheng, Y., Subramanyam, M., & Wang, Y. (2010) · Trends in biotechnology · doi:10.1016/j.tibtech.2010.07.001 · Cited by 101 · see citing works
Galson, J. D., Trück, J., Fowler, A., Clutterbuck, E. A., Münz, M., Cerundolo, V., Reinhard, C., van der Most, R., Pollard, A. J., Lunter, G., et al. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.11.034 · Cited by 97 · see citing works
Immunogenicity of rituximab in patients with severe pemphigus
Schmidt, E., Hennig, K., Mengede, C., Zillikens, D., & Kromminga, A. (2009) · Clinical Immunology · doi:10.1016/j.clim.2009.05.007 · Cited by 94 · see citing works
Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation
Ben‐Horin, S., Casteele, N. V., Schreiber, S., & Lakatos, P. L. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.05.023 · Cited by 94 · see citing works
Self-citationZoghbi, J., Xu, Y., Grabert, R. C., Theobald, V., & Richards, S. M. (2015) · Journal of Immunological Methods · doi:10.1016/j.jim.2015.08.002 · Cited by 92 · see citing works
Kopylov, U., Mazor, Y., Yavzori, M., Fudim, E., Katz, L. H., Coscas, D., Picard, O., Chowers, Y., Eliakim, R., & Ben‐Horin, S. (2011) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21919 · Cited by 84 · see citing works
Self-citationUngar, B., Engel, T., Yablecovitch, D., Lahat, A., Lang, A., Avidan, B., Har‐Noy, O., Carter, D., Levhar, N., Selinger, L., et al. (2018) · The American Journal of Gastroenterology · doi:10.1038/s41395-018-0073-0 · Cited by 83 · see citing works
Self-citationLofgren, J. A., Wala, I., Koren, E., Swanson, S. J., & Jing, S. (2005) · Journal of Immunological Methods · doi:10.1016/j.jim.2005.10.007 · Cited by 81 · see citing works
Immunogenicity of Therapeutic Antibodies: Monitoring Antidrug Antibodies in a Clinical Context
Bloem, K., Hernández‐Breijo, B., Martínez‐Feito, A., & Rispens, T. (2017) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000404 · Cited by 80 · see citing works
Bloem, K., van Leeuwen, A., Verbeek, G., Nurmohamed, M. T., Wolbink, G., van der Kleij, D., & Rispens, T. (2015) · Journal of Immunological Methods · doi:10.1016/j.jim.2015.01.007 · Cited by 77 · see citing works
Bendtzen, K. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00109 · Cited by 73 · see citing works
Proteomic Identification of Monoclonal Antibodies from Serum
Boutz, D. R., Horton, A. P., Wine, Y., Lavinder, J. J., Georgiou, G., & Marcotte, E. M. (2014) · Analytical Chemistry · doi:10.1021/ac4037679 · Cited by 73 · see citing works
Self-citationAutoreactive B-1 B cells: Constraints on natural autoantibody B cell antigen receptors
Rowley, B., Tang, L., Shinton, S. A., Hayakawa, K., & Hardy, R. R. (2007) · Journal of Autoimmunity · doi:10.1016/j.jaut.2007.07.020 · Cited by 68 · see citing works
Greiff, V., Menzel, U., Haessler, U., Cook, S. C., Friedensohn, S., Khan, T. A., Pogson, M., Hellmann, I., & Reddy, S. T. (2014) · BMC Immunology · doi:10.1186/s12865-014-0040-5 · Cited by 64 · see citing works
Rheumatoid factor interference in immunogenicity assays for human monoclonal antibody therapeutics
Tatarewicz, S. M., Miller, J. M., Swanson, S. J., & Moxness, M. S. (2010) · Journal of Immunological Methods · doi:10.1016/j.jim.2010.03.012 · Cited by 61 · see citing works
Differences in the Composition of the Human Antibody Repertoire by B Cell Subsets in the Blood
Mroczek, E. S., Ippolito, G. C., Rogosch, T., Hoi, K. H., Hwangpo, T. A., Brand, M., Zhuang, Y., Liu, C. R., Schneider, D. A., Zemlin, M., et al. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00096 · Cited by 55 · see citing works
Large-scale analysis of human heavy chain V(D)J recombination patterns
Volpe, J. M., & Kepler, T. B. (2008) · Immunome Research · doi:10.1186/1745-7580-4-3 · Cited by 48 · see citing works
Menzel, U., Greiff, V., Khan, T. A., Haessler, U., Hellmann, I., Friedensohn, S., Cook, S. C., Pogson, M., & Reddy, S. T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096727 · Cited by 47 · see citing works
The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?
Ben‐Horin, S., Heap, G., Ahmad, T., Kim, H., Kwon, T., & Chowers, Y. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2015.1091307 · Cited by 43 · see citing works
Self-citationInfliximab–Tumor Necrosis Factor Complexes Elicit Formation of Anti-Drug Antibodies
Bar‐Yoseph, H., Pressman, S., Blatt, A., Gerassy-Vainberg, S., Maimon, N., Starosvetsky, E., Ungar, B., Ben‐Horin, S., Shen-Orr, S. S., & Chowers, Y. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.08.009 · Cited by 42 · see citing works
Self-citationDavydov, A. N., Obraztsova, A., Lebedin, M. Y., Turchaninova, M. A., Staroverov, D. B., Merzlyak, E. M., Sharonov, G. V., Кладова, О. В., Shugay, M., Britanova, O. V., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02309 · Cited by 28 · see citing works
Haney, D. J., Lock, M. D., Gurwith, M., Simon, J. K., Ishioka, G. Y., Cohen, M. B., Kirkpatrick, B. D., Lyon, C. E., Chen, W. H., Sztein, M. B., et al. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.04.011 · Cited by 24 · see citing works
ASAP - A Webserver for Immunoglobulin-Sequencing Analysis Pipeline
Avram, O., Vaisman‐Mentesh, A., Yehezkel, D., Ashkenazy, H., Pupko, T., & Wine, Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01686 · Cited by 21 · see citing works
Self-citationHernández‐Breijo, B., Chaparro, M., Cano-Martínez, D., Guerra, I., Iborra, M., Cabriada, J. L., Bujanda, L., Taxonera, C., García-Sánchez, V., Marín‐Jiménez, I., et al. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.09.019 · Cited by 12 · see citing works
Flagged first, then by citations
1 of the 54 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- [54]Vaisman-Mentesh V Rosenstein S Yavzori M Dror Y Fudim E Ungar B Molecular landscape of anti-drug antibodies reveals the mechanism of the immune response following treatment with TNFα antagonists. biorxiv. (2019). 10.1101/509489 PMC6930160 31921180 · DOI
Cited by
Sorted by citations
Vaisman‐Mentesh, A., Gutiérrez-González, M., DeKosky, B. J., & Wine, Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01951 · Cited by 295 · see citing works
Self-citationComputational and artificial intelligence-based methods for antibody development
Kim, J., McFee, M., Fang, Q., Abdin, O., & Kim, P. M. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.12.005 · Cited by 178 · see citing works
Review: Local Tumor Necrosis Factor-α Inhibition in Inflammatory Bowel Disease
Gareb, B., Otten, A. T., Frijlink, H. W., Dijkstra, G. D. H., & Kosterink, J. G. W. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12060539 · Cited by 112 · see citing works
Assessing developability early in the discovery process for novel biologics
Fernández‐Quintero, M. L., Ljungars, A., Waibl, F., Greiff, V., Andersen, J. T., Gjølberg, T. T., Jenkins, T. P., Voldborg, B. G. R., Grav, L. M., Kumar, S., et al. (2023) · mAbs · doi:10.1080/19420862.2023.2171248 · Cited by 99 · see citing works
BNT162b2 mRNA vaccine elicited antibody response in blood and milk of breastfeeding women
Rosenberg-Friedman, M., Kigel, A., Bahar, Y., Werbner, M., Alter, J., Yogev, Y., Dror, Y., Lubetzky, R., Dessau, M. A., Gal-Tanamy, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26507-1 · Cited by 70 · see citing works
Self-citationMosch, R., & Guchelaar, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.885672 · Cited by 63 · see citing works
Anti-Drug Antibody Response to Therapeutic Antibodies and Potential Mitigation Strategies
Howard, E. L., Goens, M. M., Susta, L., Patel, A. R., & Wootton, S. K. (2025) · Biomedicines · doi:10.3390/biomedicines13020299 · Cited by 58 · see citing works
Llamanade: An open-source computational pipeline for robust nanobody humanization
Sang, Z., Xiang, Y., Bahar, İ., & Shi, Y. (2021) · Structure · doi:10.1016/j.str.2021.11.006 · Cited by 52 · see citing works
Progress and challenges in mass spectrometry-based analysis of antibody repertoires
Snapkov, I., Chernigovskaya, M., Sinitcyn, P. G., Quý, K. L., Nyman, T. A., & Greiff, V. (2021) · Trends in biotechnology · doi:10.1016/j.tibtech.2021.08.006 · Cited by 50 · see citing works
Approaches for the detection and analysis of antidrug antibodies to biopharmaceuticals: A review
Suh, K., Kyei, I., & Hage, D. S. (2022) · Journal of Separation Science · doi:10.1002/jssc.202200112 · Cited by 41 · see citing works
Tang, Y., & Cao, Y. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030422 · Cited by 38 · see citing works
Gjølberg, T. T., Frick, R., Mester, S., Foss, S., Grevys, A., Høydahl, L. S., Jørstad, Ø. K., Schlothauer, T., Sandlie, I., Moe, M. C., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03787-x · Cited by 37 · see citing works
Rienzo, A. D., Marinelli, L., Dimmito, M. P., Toto, E. C., Stefano, A. D., & Cacciatore, I. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16091185 · Cited by 33 · see citing works
Baker, D., Ali, L., Saxena, G., Pryce, G., Jones, M., Schmierer, K., Giovannoni, G., Gnanapavan, S., Munger, K. C., Samkoff, L., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00124 · Cited by 33 · see citing works
Engineering of anti-human interleukin-4 receptor alpha antibodies with potent antagonistic activity
Kim, J.-E., Jung, K., Kim, J.-A., Kim, S., Park, H., & Kim, Y. (2019) · Scientific Reports · doi:10.1038/s41598-019-44253-9 · Cited by 30 · see citing works
Proposal of International Council for Harmonization (ICH) Guideline for the Approval of Biosimilars
Niazi, S. K., Al-Shaqha, W. M., & Mirza, Z. (2022) · Journal of Market Access & Health Policy · doi:10.1080/20016689.2022.2147286 · Cited by 29 · see citing works
Scientific Rationale for Waiving Clinical Efficacy Testing of Biosimilars
Niazi, S. K. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s378813 · Cited by 28 · see citing works
ASAP - A Webserver for Immunoglobulin-Sequencing Analysis Pipeline
Avram, O., Vaisman‐Mentesh, A., Yehezkel, D., Ashkenazy, H., Pupko, T., & Wine, Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01686 · Cited by 21 · see citing works
Self-citationRoy, S., Curry, S. D., Bagot, C. C., Mueller, E. N., Mansouri, A. M., Park, W., Cha, J. N., & Goodwin, A. P. (2022) · ACS Nano · doi:10.1021/acsnano.2c02558 · Cited by 20 · see citing works
Vaisman‐Mentesh, A., Dror, Y., Tur‐Kaspa, R., Markovitch, D., Kournos, T., Dicker, D., & Wine, Y. (2020) · medRxiv · doi:10.1101/2020.08.23.20179796 · Cited by 20 · see citing works
Self-citationAnti-drug antibodies in the current management of cancer
Borregón, M., Martínez, K., Ramos, A., Ramos, I., Berzal, B., Mazariegos, M., Martínez, E., Hernández, T., Doger, B., & Moreno, V. (2022) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-022-04418-2 · Cited by 19 · see citing works
Structure and Dynamics Guiding Design of Antibody Therapeutics and Vaccines
Fernández‐Quintero, M. L., Pomarici, N. D., Fischer, A.-L. M., Hoerschinger, V. J., Kroell, K. B., Riccabona, J. R., Kamenik, A. S., Loeffler, J. R., Ferguson, J. A., Perrett, H. R., et al. (2023) · Antibodies · doi:10.3390/antib12040067 · Cited by 19 · see citing works
Kuo, W., Lee, C., Chang, Y.-W., Pang, W., Chen, H., Hou, S., Lo, S., Yang, A., & Wang, A. H. ‐. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2020.166766 · Cited by 19 · see citing works
PASA: Proteomic analysis of serum antibodies web server
Avram, O., Kigel, A., Vaisman‐Mentesh, A., Kligsberg, S., Rosenstein, S., Dror, Y., Pupko, T., & Wine, Y. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008607 · Cited by 19 · see citing works
Self-citationPetrić, Z., Gonçalves, J., & Paixão, P. J. P. A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091766 · Cited by 18 · see citing works
Nielsen, O. H., Hammerhøj, A., Ainsworth, M. A., Gubatan, J. M. B., & D’Haens, G. (2024) · Drugs · doi:10.1007/s40265-024-02115-3 · Cited by 18 · see citing works
Custers, M., Wouters, Y., Jaspers, T., Bundel, D. D., Dewilde, M., Eeckhaut, A. V., & Smolders, I. J. (2021) · Analytica Chimica Acta · doi:10.1016/j.aca.2021.338803 · Cited by 17 · see citing works
Joyce, A. P., Shea, C., You, Z., Gorovits, B., & Lepsy, C. S. (2022) · The AAPS Journal · doi:10.1208/s12248-022-00759-1 · Cited by 16 · see citing works
Immunogenicity of dupilumab in adult and pediatric patients with atopic dermatitis
Kamal, M. A., Kosloski, M. P., Lai, C., Partridge, M. A. K., Rajadhyaksha, M., Kanamaluru, V., Bansal, A., Shabbir, A., Shumel, B. S., Ardeleanu, M., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1466372 · Cited by 15 · see citing works
Yau, T. O., Vadakekolathu, J. N., Foulds, G. A., Du, G., Polytarchou, C., Dickins, B., & Rutella, S. (2021) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15764 · Cited by 13 · see citing works
Radiolabeled NGR-Based Heterodimers for Angiogenesis Imaging: A Review of Preclinical Studies
Trencsényi, G., Halmos, G., & Képes, Z. (2023) · Cancers · doi:10.3390/cancers15184459 · Cited by 12 · see citing works
Ding, X., Xue, L., Wang, M., Zhu, S., Zhu, K., Jiang, S., Wu, J. H., & Miao, L. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1429544 · Cited by 12 · see citing works
The Wound Healing Peptide, AES16-2M, Ameliorates Atopic Dermatitis In Vivo
Kim, M. S., Song, J., Park, S., Kim, T. S., Park, H. J., & Cho, D. (2021) · Molecules · doi:10.3390/molecules26041168 · Cited by 10 · see citing works
Production of F(ab′)2 from Monoclonal and Polyclonal Antibodies
Rosenstein, S., Vaisman‐Mentesh, A., Levy-Kanfo, L., Kigel, A., Dror, Y., & Wine, Y. (2020) · Current Protocols in Molecular Biology · doi:10.1002/cpmb.119 · Cited by 8 · see citing works
Self-citationAntidrug antibodies to adalimumab do not associate with immunologically related adverse events
Tourdot, S., Vazquez-Abad, M.-D., Cox, D. S., Cai, C.-H., Wang, K., Zhang, W., & Lepsy, C. S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1457993 · Cited by 7 · see citing works
Gareb, B., Beugeling, M., Posthumus, S., Otten, A. T., Dijkstra, G. D. H., Kosterink, J. G. W., & Frijlink, H. W. (2021) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2021.102552 · Cited by 7 · see citing works
Rusche, H., Marrani, E., Real‐Fernández, F., Ponti, R., Terzani, F., Maccora, I., Monasson, O., Mastrolia, M. V., Peroni, E., Pagnini, I., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-95920-9 · Cited by 7 · see citing works
A novel Shiga toxin 2a neutralizing antibody therapeutic with low immunogenicity and high efficacy
Kirkland, M. E., Patfield, S. A., Hughes, A. C., Hernlem, B. J., & He, X. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00598-23 · Cited by 6 · see citing works
Deep Mining of Human Antibody Repertoires: Concepts, Methodologies, and Applications
Tian, X., Li, C., Wu, Y., & Ying, T. (2020) · Small Methods · doi:10.1002/smtd.202000451 · Cited by 6 · see citing works
Furihata, K., Hamada, I., Niwa, T., Watanabe, T., & Ezoe, S. (2022) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1065 · Cited by 5 · see citing works
Bergan, S., & Vethe, N. T. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16170 · Cited by 4 · see citing works
Advances in immunotoxin engineering: precision therapeutic strategies in modern oncology
Oghalaie, A., Hosseini, M. E., Hosseininejad-Chafi, M., Eftekhari, Z., Behdani, M., & Kazemi‐Lomedasht, F. (2024) · Medical Oncology · doi:10.1007/s12032-024-02478-3 · Cited by 4 · see citing works
Silveira, P. A., Kupresanin, F., Romano, A., Hsu, W., Lo, K., Ju, X., Chen, H.-T., Roberts, H., Baker, D. G., & Clark, G. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.784528 · Cited by 4 · see citing works
Han, L., Lin, G., Lv, X., Li, S., Huang, Z., Li, Y., Chen, D., Chen, X., Lin, J., Chen, L., et al. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s556906 · Cited by 3 · see citing works
Williams, J. H., Liao, K., Yin, D., & Meng, X. (2024) · The AAPS Journal · doi:10.1208/s12248-024-00901-1 · Cited by 3 · see citing works
A single point mutation on FLT3L-Fc protein increases the risk of immunogenicity
Qin, D., Phung, Q. T., Wu, P., Yin, Z., Tam, S., Tran, P., ElSohly, A. M., Gober, J. G., Hu, Z., Zhou, Z., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1519452 · Cited by 3 · see citing works
Ogwang, R., Murugu, L., Nkumama, I. N., Nyamako, L., Kai, O. K., Mwai, K., Murungi, L., Idro, R., Bejon, P., Tuju, J., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1360220 · Cited by 2 · see citing works
Sun, M., Ju, J., Xu, H., Luo, M., Li, Z., & Wang, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1360835 · Cited by 2 · see citing works
Detection of anti-drug antibodies during monoclonal antibody drug therapy
Kokojka, F., Mulleman, D., & Marks, R. S. (2026) · Trends in biotechnology · doi:10.1016/j.tibtech.2026.04.003 · Cited by 1 · see citing works
Querejazu, M. O., Dunn, N., Ramanujam, R., Ryner, M. L., Auer, M., Jensen, P. E., Deisenhammer, F., & Fogdell‐Hahn, A. (2022) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2022.103815
Jiang, Q., Guan, J., Yu, D., Singh, P., Pelekos, G., Lo, E. C. M., & Wang, J. (2026) · Antibody Therapeutics · doi:10.1093/abt/tbag039
- Authors
- Vaisman-Mentesh, A., Rosenstein, S., Yavzori, M., Dror, Y., Fudim, E., Ungar, B., Kopylov, U., Picard, O., Kigel, A., Ben-Horin, S., Benhar, I., & Wine, Y.
- Affiliations
- Tel Aviv University (IL)
- Corresponding author
- Wine, Yariv
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2019-12-18
- Volume
- 10
- Pages
- 2921-2921
- ISSN
- 1664-3224 (ISSN-L)
- PMC
- PMC6930160
- OpenAlex
- W2991056046
- Cited by
- 54
- References
- 54
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 9 · 2023: 5 · 2022: 12 · 2021: 12 · 2020: 7 · 2019: 2 · 2018: 1
- FWCI
- 5.45
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Immunology (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- University of Texas at Austin
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Keywords
- anti-drug antibodies, monoclonal antibodies, immunogenicity, antibody neutralization, lambda light chain, T cell-independent immune response, extrafollicular B cells
- MeSH terms
- Antibodies, Monoclonal, Humans, Immunoassay, Tumor Necrosis Factor-alpha
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
